Streetbeat News

Analyst Ratings

BKNG

Piper Sandler analyst Thomas Champion has maintained a Neutral rating on Booking Holdings (NASDAQ:BKNG) and lowered the price target from $3110 to $2900.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:08 pm

ROK

Mizuho analyst Brett Linzey has maintained a Neutral rating on Rockwell Automation (NYSE:ROK) and lowered the price target from $270 to $265.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:07 pm

CYBR

Mizuho analyst Gregg Moskowitz maintains a 'Buy' rating on CyberArk Software (NASDAQ:CYBR) and raises the price target from $175 to $195.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:05 pm

BOOT

Piper Sandler analyst Peter Keith has maintained an Overweight rating on Boot Barn Holdings (NYSE:BOOT) but lowered the price target from $120 to $99.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:04 pm

TYL

Oppenheimer analyst Ken Wong maintains an Outperform rating on Tyler Technologies (NYSE:TYL) and raises the price target from $450 to $480.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:03 pm

AAPL

AMD

LLY

NVO

QCOM

The Federal Reserve held interest rates steady, soothing investors and sparking a market rally. Robust earnings reports also boosted investor sentiment. The labor market showed signs of softening, with job gains slowing and unemployment rising. Apple, Advanced Micro Devices, and Qualcomm outperformed expectations, while Novo Nordisk and Eli Lilly beat estimates. Upcoming earnings reports from Vertex Pharmaceuticals, Gilead Sciences, Uber Technologies, Occidental Petroleum, Walt Disney, and Becton Dickinson will be closely watched.

Portfolio Pulse from Piero Cingari

November 03, 2023 | 8:03 pm

KA

Kineta, Inc. (NASDAQ:KA) presented new preclinical data on its lead anti-CD27 monoclonal antibody at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data showed high binding affinity and specificity, strong T cell activation and proliferation, and NK cell activation. The antibody demonstrated in vivo antitumor efficacy as a single agent and in combination with other immunotherapies in multiple solid and hematological mouse tumor models.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:01 pm

BKNG

Oppenheimer analyst Jed Kelly has maintained an 'Outperform' rating on Booking Holdings (NASDAQ:BKNG) but lowered the price target from $3700 to $3450.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:00 pm

LRCX

A whale investor has taken a bullish stance on Lam Research (NASDAQ:LRCX), with 68% of investors opening trades with bullish expectations. The whale has been targeting a price range from $530.0 to $665.0 for Lam Research over the last 3 months. The price of LRCX is up 1.84% at $634.77. Needham upgraded its action to Buy with a price target of $800, while UBS, B. Riley Securities, and JP Morgan maintained their Buy, Neutral, and Overweight ratings respectively.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:00 pm

DIN

Dine Brands Global (NYSE:DIN) has received seven analyst ratings in the last quarter, with two being bullish, three somewhat bullish, and two indifferent. The average price target is $59.14, representing an upside from the current price of $44.68. This average is a 10.84% decrease from the previous average price target of $66.33.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 8:00 pm